** Shares of China Medical System Holdings 0867.HK rise 4% to HK$8.54, their highest since February 27
** Stock set for the biggest one-day rise since February 26; on track for fourth straight session of gains
** The Chinese medicine producer says China's National Medical Products Administration has granted drug clinical trials approval to its Cardiac Myosin Inhibitor CMS-D003, which is a targeted therapy for hypertrophic cardiomyopathy
** Co, with market capitaliation of HK$20.64 bln ($2.66 bln), says CMS-D003 can also be developed for the treatment of heart failure with preserved ejection fraction in the future
** Hong Kong's healthcare index .HSCIH and Hang Seng Index .HSI both slip 0.7%
** Stock up 8.7% YTD
($1 = 7.7713 Hong Kong dollars)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。